About STENTiT
STENTiT is a company based in Eindhoven (Netherlands) founded in 2007 by Bart Sanders. STENTiT has raised $1.94 million across 5 funding rounds from investors including EIT Health, European Union and BOM. STENTiT offers products and services including Resorbable Fibrillated Scaffold (RFS). STENTiT operates in a competitive market with competitors including SMT, InspireMD, Vesper Medical, Endospan and Biosensors International, among others.
- Headquarter Eindhoven, Netherlands
- Founders Bart Sanders
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Stentit B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.94 M (USD)
in 5 rounds
-
Latest Funding Round
$2.7 M (USD), Grant
Sep 01, 2023
-
Investors
EIT Health
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of STENTiT
STENTiT offers a comprehensive portfolio of products and services, including Resorbable Fibrillated Scaffold (RFS).
Provides temporary vascular support to restore blood flow and facilitate artery healing.
People of STENTiT
Unlock access to complete
Unlock access to complete
Funding Insights of STENTiT
STENTiT has successfully raised a total of $1.94M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2.7 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $2.7M
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Grant - STENTiT | Valuation |
investors |
|
| Apr, 2022 | Amount | Seed - STENTiT | Valuation | NextGen Ventures , BOM | |
| Aug, 2018 | Amount | Grant - STENTiT | Valuation |
investors |
Investors in STENTiT
STENTiT has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Health, European Union and BOM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments are directed by BOM toward early and growth-stage firms.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by STENTiT
Financial Statements - STENTiT
Stentit Comparisons
Competitors of STENTiT
STENTiT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SMT, InspireMD, Vesper Medical, Endospan and Biosensors International, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
SMT is recognized as a developer of cardiovascular medical devices.
|
|
| domain | founded_year | HQ Location |
Proprietary stent systems with bio-stable mesh are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Venous stent system is developed for deep vein disease treatment.
|
|
| domain | founded_year | HQ Location |
Endovascular stent graft systems for aortic aneurysm repair are developed.
|
|
| domain | founded_year | HQ Location |
Products for interventional cardiology and critical care procedures
|
|
| domain | founded_year | HQ Location |
Three-dimensional vascular stents for peripheral vascular disease are developed.
|
Latest news on Stentit
Frequently Asked Questions about STENTiT
STENTiT was founded in 2007 and raised its 1st funding round 7 years after it was founded.
STENTiT is headquartered in Eindhoven, Netherlands. It is registered at Eindhoven, Noord-brabant, Netherlands.
Bart Sanders is the current CEO of STENTiT. They have also founded this company.
STENTiT is a funded company, having raised a total of $1.94M across 5 funding rounds to date.
The company was founded in 2007 in Eindhoven, Netherlands, and operates in the medical devices sector focused on cardiovascular treatments. Regenerative endovascular implants are developed to address vascular disorders through a catheter-based approach that restores arteries without invasive surgery. These stents feature a biodegradable supportive porous structure designed for implantation in affected arteries. Leadership includes co-founder and CEO Bart Sanders.
STENTiT offers Resorbable Fibrillated Scaffold (RFS).
STENTiT has 7 investors. Key investors include EIT Health, European Union, BOM, NWO, and NextGen Ventures.